We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
- Authors
François, Eric; Berdah, Jean-François; Chamorey, Emmanuel; Lesbats, Gérard; Teissier, Eric; Codoul, Jean-François; Badetti, Jean-Luc; Hébert, Christophe; Mari, Véronique
- Abstract
The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer. Patients with metastatic colorectal cancer included in this study were aged at least 70 years, with a performance status of 0/1, without geriatric syndrome and without previous palliative chemotherapy. They received irinotecan [180 mg/m2 intravenous (iv) infusion over 90 min] followed by folinic acid (400 mg/m2 iv over 2 h), then 5FU (400 mg/m2 iv bolus) and 5FU (2,400 mg/m2 continuous iv infusion for 46 h) every 2 weeks. Forty eligible patients were included. The median age was 77.3 years (range 70–84.7). The objective response rate was 40% and the stabilisation rate was 45%. Median progression-free survival was 8 months, overall survival was 17.2 months and cancer-related specific survival was 20.2 months. In total, 300 cycles of chemotherapy were administered with a median number of eight cycles per patient (range 1–18). Tolerance was good; grade 3/4 toxicities included diarrhoea (15%), asthenia (15%), nausea/vomiting (7.5%) and neutropenia (7.5%). One toxic death was observed due to grade 4 diarrhoea. The FOLFIRI 1 regimen is a valid therapeutic option for elderly patients in good clinical condition.
- Subjects
CANCER patients; CANCER treatment; INTESTINAL diseases; DIARRHEA; TECHNICAL specifications
- Publication
Cancer Chemotherapy & Pharmacology, 2008, Vol 62, Issue 6, p931
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-008-0681-2